Christopher Posner News Today

STAMFORD, Conn., April 02, 2024 -- Cara Therapeutics, Inc. , a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from...

Stamford-based Cara Therapeutics Inc. (NASDAQ: CARA) is laying off part of its workforce in an effort to reduce operating costs while shifting its primary focus to developing a drug to treat notalgia paresthetica (NP), a neuropathic disorder for which here is no federally approved therapy.

22.01.2024 - – Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce reduction of up to 50% – – Cara ... Seite 1

– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all...

– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025–

Cara Therapeutics Inc., a Stamford-headquartered commercial-stage biopharmaceutical company focused on creating a new treatment paradigm to improve the lives of patients suffering from pruritus, has entered into a royalty interest purchase and sale agreement with HealthCare Royalty (HCRx), also based in Stamford.

Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call Transcript August 7, 2023 Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.00058 EPS, expectations were $0.56. Operator: Thank you for standing by, and welcome to Cara Therapeutics’ Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions]. […]

Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) CEO Christopher Posner sold 4,307 shares of the stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $3.07, for a total value of $13,222.49. Following the completion of the sale, the chief executive officer now directly owns 168,207 shares […]

Cara Therapeutics and VFMCRP have announced that the US’s NICE has recommended Kapruvia (difelikefalin) to treat CKD-associated pruritus.

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus